



**QUEEN'S  
UNIVERSITY  
BELFAST**

## **Validation, usability and acceptability of SARS-CoV-2 loop mediated isothermal amplification test in Malawi**

Waterfield, T. (2024). *Validation, usability and acceptability of SARS-CoV-2 loop mediated isothermal amplification test in Malawi*. Poster session presented at CROI 2024, Colorado.

### **Document Version:**

Publisher's PDF, also known as Version of record

### **Queen's University Belfast - Research Portal:**

[Link to publication record in Queen's University Belfast Research Portal](#)

### **Publisher rights**

Copyright 2024 the authors.

### **General rights**

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### **Take down policy**

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [openaccess@qub.ac.uk](mailto:openaccess@qub.ac.uk).

### **Open Access**

This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: <http://go.qub.ac.uk/oa-feedback>

# Validation, Usability and Acceptability of SARS-CoV-2 Loop Mediated Isothermal Amplification test in Malawi

Maggie Nyirenda - Nyang'wa<sup>1</sup>, Mercy Kamdolozi<sup>2</sup>, Harry Meleke<sup>2</sup>, David Chaima<sup>2</sup>, Vincent S. Phiri<sup>2</sup>, Thomas Waterfield<sup>3</sup>, Nedson Bondera<sup>4</sup>, Maganizo B. Chagomerana<sup>5,6</sup>, James McKenna<sup>3</sup>, Alice Lwanda<sup>2</sup>, Vinjeru Chavula<sup>2</sup>, Bright Mbvundula<sup>2</sup>, Margaret Nkhonjera<sup>2</sup>, Thoko Noniwa<sup>4</sup>, Dr Tiwonge E. Phiri<sup>4</sup>, Dr Tamara J. Phiri<sup>4</sup>, Evaristar Kudowa<sup>5</sup>, Thandie Mwalukomo<sup>2</sup>, Chisomo Msefula<sup>2</sup>, Tonney Nyirenda<sup>2</sup>, Derek Fairley<sup>3</sup>, Mina C. Hosseinipour<sup>5,6</sup>,

<sup>1</sup>University College London, London, UK, <sup>2</sup>Kamuzu University of Health Sciences, Blantyre, Malawi, <sup>3</sup>Queen's University Belfast, Belfast, United Kingdom, <sup>4</sup>Queen Elizabeth Central Hospital, Blantyre, Malawi, <sup>5</sup>University of North Carolina Project-Malawi, Lilongwe, Malawi, <sup>6</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

## BACKGROUND

Real-time-reverse-transcription-Polymerase-Chain-Reaction (RT-PCR) is the gold-standard diagnostic test to confirm SARS-CoV-2 infection however RT-PCR is expensive requiring specialist laboratories. Alternatively, optimised nucleic-acid-tests such as SARS-CoV-2-reverse-transcriptase-Loop-mediated-isothermal-AMplification (SARS-LAMP) could minimise costs and enable testing in settings without specialist laboratories

## AIM

We evaluated the diagnostic test accuracy (DTA)- (sensitivity detecting cycle-threshold (CT) values <30; specificity >95%), acceptability and user-friendliness of SARS-LAMP test.

## METHODS

- Phase 1 - Optimisation of RNA extraction free SARS-LAMP
- Phase 2 - Prospective diagnostic study using a bench top SARS-LAMP assay in Genie II instrument
- Nasopharyngeal swabs were collected and tested for SARS-COV-2 by lab technicians
- Consecutively recruited participants aged 16-80 years, n=450. attending Queen-Elizabeth-Central-Hospital (QECH) COVID-19 testing centre in Malawi.
- Study period:-September 2021-January 2022
- Usability assessed by semi – structured questionnaires, n=4.
- Acceptability assessed by semi-structured interviews (SSI), n=68.



Figure 1 : SARS –LAMP testing process




Figure 2 : Study Outline


SARS–LAMP’s sensitivity is comparable to published reports.

Sensitivity = 73%

Specificity = 100%

It is acceptable to cases and contacts of COVID-19  
User-friendly to lab technicians but varied responses on its adoption and implementation

## METHODS - Study site



## RESULTS

Table 1 Characteristics of the study participants

	Neg 261 (58%)	Cases 189 (42%)	
Age			
<40 years	137 (56.6%)	105 (43.4%)	242 (54%)
>40-55 year	79 (62.7%)	47 (37.7%)	126 (28%)
>55 year	45(54.9%)	37(45.1%)	82 (18%)
	chi <sup>2</sup> 1.66, pr 0.44		
Sex			
Male	154 (62.0%)	94 (38.0%)	248 (55%)
female	107 (53.0%)	95 (47%)	202 (45%)
	chi <sup>2</sup> 3.81, pr 0.05		
Vaccination			
Unvaccinated	157 (60.6%)	102 (39.4%)	259 (58%)
Vaccinated	103 (54.2%)	88 (45.8%)	191 (42%)
	chi <sup>2</sup> 1.88, pr 0.17		
Education			
Primary	70 (53.0%)	62 (47.0%)	132 (31%)
Secondary	108 (72.5%)	41 (27.5%)	149 (35%)
Tertiary	68 (57.9%)	76 (42.1%)	144 (34%)
	chi <sup>2</sup> 21.02, pr 0.00		

### Other Demographics

- Among the 450 participants, 8 had travelled abroad
- 233/450 (52%) had comorbidities,,
- 5/192(3%) were admitted to ICU, 2 deaths occurred.


Table 2 Sensitivity and Specificity of SARS - LAMP in comparison to qPCR

PROSPECTIVE n=450	
Sensitivity	73.6%(95% CI:63.0%-82.4%);
Specificity	100% 95% CI:98.6%-100.0%).

### Acceptability to to cases and contacts of COVID-19

- 68 participants were recruited,
- median age was 37 years (IQR of (27, 50)),
- (12/68 (17.6%) were aged >55 years
- 27/68 (40.0%) were female
- SARS-LAMP was acceptable to cases and contacts of COVID-19
- 67/68 (98%) response rate by cases and contacts of COVID-19

### Usability of SARS-LAMP by laboratory technicians



All 4 Laboratory technicians were recruited

- All 4 found SARS-LAMP user-friendly but collecting nasopharyngeal swabs from patients was not easy.
- All 4 stated that rapid antigen tests were easier to use but still 3/4 were in favour of SARS LAMP.

## CONCLUSION

### SARS -LAMP:

- Performance - highly sensitive and specific as per published studies
- Acceptable to cases and contacts of COVID-19
- Easy to use by laboratory technicians suggesting that its use is acceptable to both cases and contacts of COVID-19
- These preliminary results may suggest that implementing SARS-LAMP could significantly improve diagnosis of SARS but there are other user-friendly tests , thereby decreasing its adoption by laboratory technicians and implementation
- There is need for cost-effectiveness analyses before any scale up plans of SARS LAMP

## Acknowledgements

Study participants, Queen Elizabeth Central Hospital teams



## References

- Chih-Cheng Lai , Int J Antimicrob Agents. 2020 MZhang Y,ar;55(3)
- Zhang Y, MedRxiv. 2020 Feb 29:2020-02.. Mar 1;136:
- Schellenberg JJ, Journal of Clinical Virology. 2021 Nov;31(6)
- Chaouch M, Reviews in medical virology. 2021 Nov;31(6)
- Gärtner K , Virology journal. 2022 Dec;19(1):1-9.
- Baba MM, EClinicalMedicine. 2021;40:101101.